CD274 and breast carcinoma: A study has demonstrated that monoclonal antibodies against PD-1/PD-L1 demonstrate prominent effectiveness in patients with different types of cancers, such as non-small-cell lung cancer (NSCLC), HNSCC, melanoma, colorectal cancer, and breast cancer [80–84].